Sanofi S.A.

Sanofi is a top-tier global biopharmaceutical company that has, over six years, deliberately narrowed itself from a diversified healthcare conglomerate into a single-segment, R&D-led specialty medicines and vaccines business. Its centre of gravity is immunology: Dupixent, co-developed with Regeneron, generated €15.7bn in FY2025 — 36% of group sales — and management now guides to approximately €25bn by 2030. Around that core sit a differentiated rare-disease franchise (Pompe, Gaucher, Fabry, haemophilia, ASMD), the world's broadest vaccines portfolio outside Merck and GSK, and a smaller oncology and neurology presence. The company shed EUROAPI in 2022 and sold control of Opella consumer health to CD&R in 2025 for €10.4bn net. Financially it is unusually clean — 77.5% business gross margin, 0.8x net debt/EBITDA, 31 consecutive years of dividend increases. The unresolved question, and the reason for a February 2026 CEO change, is whether its internal pipeline can replace Dupixent's eventual erosion.

Caveat: Sanofi does not publish a single headline headcount in its quarterly releases. The FY2021 figure derives from the company's 2022 employee share plan disclosure ("over 90,000 employees in 73 countries" eligible in 2021); the FY2024/FY2025 figure of ~83,000 is the company-sourced number cited in industry reporting at the time of the March 2025 US investment announcement, reflecting both restructuring and the Opella separation. Precise year-end FTE counts are disclosed in the Universal Registration Document / Form 20-F and are not restated here. The 2025 employee share plan was offered to "around 70,000 employees in 55 countries" — an eligibility population, not total headcount.

What Sanofi does

Sanofi researches, develops, manufactures and commercialises prescription medicines and human vaccines. Since January 1, 2025 it reports one operating segment, Biopharma, plus an immaterial "Other" line that captures residual Opella-related transitional revenues and manufacturing services.

Sanofi's own characterisation, used verbatim in every 2026 press release, is: "Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world." The formal segment description in its 2025 shelf-registration prospectus reads: "We have one operating segment: Biopharma. It comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises plus support and corporate functions, for all geographical territories."

Internally, and in the reporting taxonomy adopted from FY2025, the business is organised as:

Pharma: - Immunology — Dupixent, Kevzara

• Rare diseases — Fabrazyme, Cerezyme/Cerdelga, Myozyme/Nexviazyme, Aldurazyme, Xenpozyme, ALTUVIIIO, Eloctate, Alprolix, Cablivi, Qfitlia, Wayrilz, Ayvakit

• Neurology — Aubagio (in run-off), Cenrifki (tolebrutinib)

• Oncology — Sarclisa, Jevtana, Fasturtec

• Other main / established medicines — Lantus, Toujeo, Apidra, Soliqua, Plavix, Lovenox, Aprovel, Multaq, Praluent, Thymoglobulin, Rezurock, Synvisc

Vaccines: influenza (Fluzone/Efluelda/Vaxigrip), polio/pertussis/Hib (Pentacel, Pentaxim, Hexaxim, Vaxelis via JV), meningitis (Menactra, MenQuadfi), travel/endemic (rabies, yellow fever, typhoid, hepatitis A), Beyfortus (RSV mAb, with AstraZeneca), Nuvaxovid (COVID-19), Heplisav-B (adult hepatitis B, acquired with Dynavax)

Revenue model

Sanofi's revenue is overwhelmingly product sales of patented and off-patent pharmaceuticals and vaccines — there is effectively no subscription or service revenue. The economics have four distinct layers:

1. Net sales (€43,626m FY2025) — gross invoiced product sales less gross-to-net deductions (US rebates, Medicaid/340B, chargebacks, ex-US statutory price cuts, China VBP/NRDL).

2. Other revenues (€3,090m FY2025) — a materially different-margin stream comprising VaxServe's distribution of non-Sanofi vaccines in the US (€1,780m FY2025, declining), manufacturing services (€557m), transitional sales of Opella products in certain markets (€487m), and royalties (€146m).

3. Alliance profit-sharing, recorded in other operating income/expenses — this is the single most important non-obvious feature of Sanofi's P&L. Sanofi books 100% of worldwide Dupixent and Kevzara sales but must then pay Regeneron its share of alliance profit. In FY2025 the total charge related to Regeneron was €4,923m, of which €5,065m was the monoclonal-antibody alliance net (profit/loss share −€5,455m, plus €1,089m of Regeneron's contribution to development costs, less €699m reimbursement of Regeneron commercial operating expenses). This charge grew 28% year-on-year and structurally caps Sanofi's operating leverage on its fastest-growing asset.

4. Out-licensing royalties — notably the Amvuttra royalty (€398m in H1 2026, up from €120m in H1 2025) and other license-out income (€495m FY2025).

Value chain position and customers

Sanofi is a fully integrated originator: discovery research, clinical development, regulatory, primary and secondary manufacturing (biologics, sterile injectables, vaccine bulk and fill-finish), and direct commercialisation in most markets. It also operates VaxServe, a US vaccine and specialty-pharmaceutical distribution business that carries third-party product — a rare downstream extension.

Customers are institutional rather than retail: US wholesalers (McKesson, Cencora, Cardinal) and PBMs, national and regional health systems and tender authorities in Europe, public immunisation programmes and supranational buyers (UNICEF, PAHO, Gavi) for vaccines, hospital groups, and specialty pharmacies for rare disease and biologic products. End-markets are immunology and inflammation, rare genetic disease, haematology, multiple sclerosis, multiple myeloma, diabetes, cardiovascular disease, and paediatric and adult immunisation.

Independent characterisation

Functionally Sanofi is now one very large product (Dupixent) plus a durable but low-growth annuity book plus an option on a rebuilt pipeline. Dupixent contributed 36% of FY2025 net sales and 44.4% of Q2 2026 net sales, and grew 37.6% in Q2 2026 — meaning group growth is almost entirely one franchise. The vaccines business, historically Sanofi's defensive ballast, has become a source of volatility: it declined 1.2% in FY2025 and 1.1% in H1 2026, pressured by falling birth rates in China, US immunisation-policy uncertainty, and competitive tendering. The rare-disease and haemophilia portfolios are genuinely differentiated but individually sub-scale. The strategic problem management is now addressing is that Sanofi has bought growth (Blueprint, Dynavax, Vicebio) faster than it has generated it internally — and in July 2026 discontinued three of the assets that were supposed to be the answer.

The stated strategy, in the company's own framing

The corporate self-description used in every 2026 communication is: "an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines..." Paul Hudson's FY2025 framing was: "This momentum reflects our evolution as an R&D-driven, AI-powered biopharma company harnessing the power of science to deliver breakthroughs for patients."

Belén Garijo's first substantive public statement of direction, in the Q2 2026 release, is materially different in tone: "My first months as CEO have focused on assessing the challenges facing Sanofi and working on an accelerated transformation roadmap that leverages our commercial strengths and focuses on the need for R&D and pipeline improvements. We have taken the first decisive steps on pipeline prioritization and recently, we appointed a focused Executive Committee aligned with the strategic priorities."

The shift is explicit: from "R&D-led growth" as an aspiration to R&D productivity as a problem to be fixed, with commercial execution positioned as the reliable asset.

Financial and operational targets

Note the trajectory of the launch ambition: at the October 2023 R&D day Sanofi guided to "more than €10bn sales contribution from Pharma launches by 2030" on a risk-adjusted CER basis. Three years and multiple pipeline failures later, the figure is "approximately €10bn" — an implicit downgrade even as the Dupixent number was raised.

Strategic initiatives of the last 24 months

Portfolio reshaping

Opella separation (closed April 30, 2025): sale of control to CD&R for €10.4bn net cash, retaining a 48.2% equity interest in OPAL JV Co. The retained stake has been a drag: Sanofi's share of OPAL JV Co losses was −€310m in FY2025 (from May 1) and Opella reported a net loss of €622m for the period. Opella's standalone H1 2026: net sales and other revenues €2,657m, net loss €61m.

Vaccines consolidation: Vicebio (US$1.2bn, RSV/HMPV Molecular Clamp platform) and Dynavax (US$2.2bn, HEPLISAV-B plus a phase 1/2 shingles candidate) together represent a deliberate pivot toward adult immunisation and away from dependence on paediatric vaccines exposed to birth-rate decline.

Specialty acquisition: Blueprint Medicines (July 2025, €8.4bn cash outflow) bought a marketed, growing rare-disease asset rather than a pipeline bet.

Pipeline prioritisation — the July 2026 reset. Following a "thorough pipeline review during the second half of 2025, including of all phase 2 projects," Sanofi terminated multiple phase 2 studies. Under Garijo the cuts went deeper and hit late-stage assets:

Amlitelimab: (OX40L) will not be submitted in atopic dermatitis. Sanofi concluded that "the totality of efficacy and safety evidence generated to date does not support further development" and that it "would not represent a meaningful improvement to the standard of care." €952m impairment. This is the most significant single reversal — amlitelimab was one of the "12 potential blockbusters" flagged in 2023.

Itepekimab: (IL-33) discontinued in COPD and all chronic rhinosinusitis studies, jointly with Regeneron, after mixed AERIFY 1/2 results and "changes in the competitive landscape."

Balinatunfib: (oral TNFR1 signalling inhibitor, formerly SAR441566) discontinued after interim phase 2 analyses in Crohn's disease and ulcerative colitis failed internal efficacy expectations.

• Pipeline project count fell from 94 (Q3 2025) → 80 (Q4 2025) → 61 (Q2 2026), with potential new medicines and vaccines falling from 44 → 40 → 36. The stated therapeutic focus narrowed from "four main disease areas (Immunology, Rare diseases, Neurology, and selectively in Oncology) and Vaccines" to "three main areas (Immunology, Rare diseases, and Vaccines) and selectively in the disease areas of Neurology and Oncology."

US policy accommodation. The December 19, 2025 MFN agreement is the most consequential regulatory initiative. It commits Sanofi to: MFN pricing for state Medicaid programmes (average −61% on certain diabetes, cardiovascular, neurological and oncology medicines); direct-to-patient access via TrumpRx.gov and Sanofi's own affordability programme (average savings near 70% on certain anti-infectives, cardiovascular and diabetes medicines, including insulins); "a more balanced approach on pricing in other high-income economies"; and the US$20bn US investment. Sanofi was one of nine companies announced together on December 19, 2025, joining Pfizer, AstraZeneca, EMD Serono, Eli Lilly and Novo Nordisk, in exchange for a three-year suspension of potential pharmaceutical import tariffs. Note the reciprocal commitment: the agreement pushes Sanofi to seek higher prices in Europe.

Digital and AI. The "AI-powered" descriptor is now embedded in the corporate boilerplate. Sanofi maintains an in-house AI platform effort under Emmanuel Frenehard (Head of Digital, reporting directly to the CEO) and multiple external AI-discovery collaborations. Quantified financial benefit from AI is not publicly disclosed.

Immunology

Dupixent (dupilumab) — human monoclonal antibody against IL-4Rα, blocking IL-4 and IL-13 signalling; the central asset of the company. Co-developed and co-commercialised with Regeneron under a global collaboration in which Sanofi books worldwide sales and shares profit. Approved indications now span atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, COPD, bullous pemphigoid, and (from 2026, US) allergic fungal rhinosinusitis — nine FDA-approved indications. Paediatric expansion is continuous: CSU in children aged two to 11 approved in the US in Q2 2026; asthma in Japanese children aged six to 11 approved in Q4 2025. FY2025 sales €15,714m (+25.2% CER); Q2 2026 sales €5,154m (+37.6% CER), the first quarter above €5bn. Management ambition: ~€25bn by 2030 at CER. Pricing is US-net-price-driven with substantial gross-to-net deductions; quarterly comparability is frequently distorted by gross-to-net true-ups. Launch year: 2017. Notable failure: the LIBERTY-LSC programme (STYLE 1 and STYLE 2) in lichen simplex chronicus missed its primary endpoints in Q2 2026, and the EU bullous pemphigoid submission was withdrawn after EMA feedback.

Kevzara (sarilumab) — anti-IL-6 receptor monoclonal antibody, also a Regeneron alliance product. Rheumatoid arthritis and, from 2024 in the EU, polymyalgia rheumatica. FY2025 sales €507m (+23.6% CER); Q2 2026 €177m (+35.1%), the US the dominant market at €122m. A genuine second-wind product driven by the PMR indication.

Rare diseases

ALTUVIIIO (efanesoctocog alfa) — once-weekly, high-sustained factor VIII replacement for haemophilia A; the highest-value product to emerge from the Bioverativ acquisition. Launched in the US end-March 2023. FY2025 sales €1,160m (+77.6% CER), crossing both the €1bn global and US$1bn US blockbuster thresholds in its third year. Q2 2026 €349m, 87% US. Growth is switch-driven, cannibalising Sanofi's own Eloctate and taking share from non-factor therapy.

Eloctate (efmoroctocog alfa) — predecessor extended half-life FVIII. In managed decline (FY2025 €275m, −22.3%), though H1 2026 sales rose on supply to collaborator Sobi.

Alprolix (eftrenonacog alfa) — extended half-life factor IX for haemophilia B. FY2025 €603m (+7.0%). Sales are lumpy because of periodic bulk supply to Sobi, which holds the Nordic/European rights.

Qfitlia (fitusiran) — first antithrombin-lowering siRNA prophylaxis for haemophilia A and B, with or without inhibitors; low-volume subcutaneous dosing at low frequency. US approval March 2025, China approval Q4 2025. FY2025 sales €9m; Q2 2026 €7m, mostly haemophilia B. Additional phase 3 data (ATLAS-NEO) and EU/JP submissions guided for 2027.

Fabrazyme (agalsidase beta) — enzyme replacement for Fabry disease; a Genzyme legacy asset and still the franchise anchor. FY2025 €1,019m (+0.1% CER) — effectively an annuity. Note that venglustat missed its primary endpoint in Fabry disease in both the PERIDOT and CARAT phase 3 studies, removing an intended next-generation successor.

Cerezyme (imiglucerase) and Cerdelga (eliglustat) — Gaucher disease enzyme replacement and oral substrate-reduction therapy respectively. FY2025: Cerezyme €695m (−3.9%), Cerdelga €335m (+3.0%). In Q4 2025 the FDA approved a Cerezyme label extension to Gaucher disease type 3 — notably the first FDA supplemental label expansion based exclusively on real-world evidence, drawn from the International Collaborative Gaucher Group registry.

Myozyme/Lumizyme (alglucosidase alfa) and Nexviazyme/Nexviadyme (avalglucosidase alfa) — Pompe disease. Nexviazyme is systematically converting the Myozyme base: FY2025 Nexviazyme €790m (+21.4%) against Myozyme €519m (−21.0%); combined franchise roughly flat. The Baby-COMET phase 3 in infantile-onset Pompe met its primary endpoint in Q2 2026, with a US label-extension submission guided for H2 2026.

Aldurazyme (laronidase) — MPS I enzyme replacement, marketed with BioMarin. FY2025 €305m.

Xenpozyme (olipudase alfa) — first and only therapy for acid sphingomyelinase deficiency. FY2025 €228m (+54.3%); one of the fastest-growing rare-disease assets, driven by Europe and rest-of-world roll-out.

Cablivi (caplacizumab) — anti-von Willebrand factor nanobody for acquired thrombotic thrombocytopenic purpura; the flagship output of the Ablynx platform. FY2025 €271m (+12.0%). China approval and a US paediatric label extension (12 years and older) both landed in Q4 2025.

Wayrilz (rilzabrutinib) — oral BTK inhibitor with multi-immune modulation, for immune thrombocytopenia. US approval August 2025, EU Q4 2025, Japan Q2 2026. FY2025 €7m; Q2 2026 €17m. Strategically important as a platform asset: phase 3 RILIEF started in IgG4-related disease, with warm autoimmune haemolytic anaemia and sickle cell disease also in development, and phase 3 data plus US/EU submissions in IgG4-RD and wAIHA guided for 2028.

Ayvakit / Ayvakyt (avapritinib) — selective KIT D816V inhibitor for systemic mastocytosis, acquired with Blueprint Medicines in July 2025. FY2025 consolidated sales €305m (from mid-July only); full-year pro-forma sales US$725m, slightly ahead of Blueprint's own US$700–720m guidance. Q2 2026 €190m; pro-forma market sales US$221.3m, +26.4%. Note a structural negative: US government rebate obligations rose because Blueprint became part of Sanofi, costing roughly 9 percentage points of growth in Q2 2026. China rights sit with CStone Pharmaceuticals; Sanofi receives a royalty booked in Other revenues.

efdoralprin alfa (SAR447537) — recombinant alpha-1 antitrypsin for AATD-related emphysema. Demonstrated superiority to plasma-derived standard of care in the phase 2 ElevAATe study on all primary and key secondary endpoints. EU orphan designation granted Q4 2025; FDA fast track and orphan previously granted. US submission guided H2 2026.

venglustat — oral glucosylceramide synthase inhibitor. Failed in Fabry (PERIDOT, CARAT) but succeeded in type 3 Gaucher disease (LEAP2MONO). FDA priority review granted; target action date November 25, 2026. Would be the first US therapy addressing the neurological manifestations of GD3.

Neurology

Cenrifki (tolebrutinib) — brain-penetrant BTK inhibitor. A difficult asset: the HERCULES phase 3 succeeded in non-relapsing secondary progressive MS, but the FDA issued a complete response letter in late December 2025 for nrSPMS, and the PERSEUS phase 3 in primary progressive MS missed its primary endpoint, triggering a €1,663m impairment. The European Commission approved Cenrifki for SPMS without relapses in the last two years in Q2 2026, and Sanofi will launch commercially in Germany in 2026 under a mandatory risk-management programme. Drug-induced liver injury is an identified risk requiring strict monitoring. Provisionally approved in the UAE, July 2025.

Aubagio (teriflunomide) — in terminal decline post-loss of exclusivity (2023). FY2025 €238m (−35.4%). Individual sales reporting is being discontinued in 2026, with residual sales folded into "Others."

frexalimab — anti-CD40L monoclonal antibody in relapsing MS; phase 3 data and submission guided for 2027, with SPMS data in 2028. Now arguably the most important remaining neurology asset.

riliprubart — anti-C1s monoclonal antibody in chronic inflammatory demyelinating polyneuropathy. The MOBILIZE phase 3 in refractory CIDP was stopped in June 2026 after an independent data monitoring committee found it unlikely to demonstrate sufficient efficacy; the VITALIZE phase 3 in IVIg-treated CIDP continues, with data and submissions guided for 2027.

Oncology

Sarclisa (isatuximab) — anti-CD38 monoclonal antibody in multiple myeloma, approved in nearly 60 countries across four indications and used in over 60,000 patients. FY2025 €588m (+28.5%); Q2 2026 €187m (+35.7%). The IMROZ phase 3 in transplant-ineligible newly diagnosed patients drove front-line expansion. The subcutaneous formulation is the key 2026 event: approved in the EU and Japan and, as Escena, in the US, deliverable both by manual injection and via Enable Injections' CirCLIQ on-body injector — the first anticancer treatment administered by OBI. The IRAKLIA phase 3 demonstrated non-inferiority to IV with median 13-minute injection duration, identical in clinic and at home. A China SC application is under review.

Jevtana (cabazitaxel) — metastatic castration-resistant prostate cancer; genericised in Europe. FY2025 €263m (−5.9%).

Fasturtec/Elitek (rasburicase) — tumour lysis syndrome. FY2025 €175m.

Libtayo (cemiplimab) — Regeneron-originated PD-1; Sanofi's residual economics are now limited and recorded within "Total others related to Regeneron" (€142m FY2025).

Established / other main medicines

Vaccines

Vaxelis — hexavalent paediatric vaccine, a 50/50 joint venture with Merck & Co in the US. In-market sales are not consolidated; Sanofi records its share of profit in "share of profit from associates" (€179m FY2025, €74m H1 2026). Vaxelis became the US market leader in the three-dose primary series at the end of 2023.

Nuvaxovid (COVID-19) — protein-based COVID-19 vaccine originated by Novavax. EU marketing authorisation transferred to Sanofi in October 2025 and the US authorisation subsequently, giving Sanofi full commercial and regulatory responsibility.

HEPLISAV-B — two-dose adult hepatitis B vaccine acquired with Dynavax (February 2026). Reported inside the PPH line from Q1 2026; contributed materially to US vaccine growth (+77.2% in the US PPH line in Q2 2026).

Vaccine pipeline — SP0087 (vero cell rabies, EU decision H2 2026, US submission H2 2026); SP0256 (mRNA RSV alone and RSV+HMPV combination; the phase 2b showed 75% efficacy against RSV-induced lower respiratory tract disease at 5.5 months median follow-up); SP0340 (protein-based bivalent HMPV+RSV, FDA fast track, phase 1); SP0335 (H5 pandemic influenza, adjuvanted with Novavax's Matrix-M, BARDA-funded, FDA fast track, phase 2); SP0202 (pneumococcal, phase 3 data 2027); SP0218 (yellow fever, phase 3 data 2027); SP0230 (meningococcal ABCWY); Fluzone High-Dose/Efluelda label expansion to age 50+, US decision H2 2026.

Services

VaxServe — US distributor of Sanofi and third-party vaccines and specialty products; €1,780m of non-Sanofi product sales in FY2025 (−5.0% CER), recorded in Other revenues at distribution-level margins. A declining but strategically useful channel asset.

Sanofi Ventures — corporate venture arm; a further US$625m commitment was announced in Q3 2025 for biotech and digital-health investment.

Impact® — a not-for-profit brand under the Global Health Unit distributing WHO-essential standard-of-care medicines; available in 30 underserved countries as of Q2 2026.

--